Trial Profile
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Feb 2014 Results published in the Drugs and Aging.
- 02 Oct 2009 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met, according to results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
- 02 Oct 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes